RhumbLine Advisers’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $170K | Buy |
+129,536
| New | +$179K | ﹤0.01% | 3347 |
|
|
2025
Q2 | – | Sell |
-201,447
| Closed | -$91K | – | 4204 |
|
|
2025
Q1 | $91K | Buy |
201,447
+18,092
| +10% | +$10.6K | ﹤0.01% | 3417 |
|
|
2024
Q4 | $92K | Sell |
183,355
-3,543
| -2% | -$2.6K | ﹤0.01% | 3500 |
|
|
2024
Q3 | $169K | Buy |
186,898
+54,407
| +41% | +$50.4K | ﹤0.01% | 3316 |
|
|
2024
Q2 | $132K | Buy |
132,491
+17,411
| +15% | +$19.2K | ﹤0.01% | 3424 |
|
|
2024
Q1 | $170K | Buy |
115,080
+3,624
| +3% | +$4.11K | ﹤0.01% | 3253 |
|
|
2023
Q4 | $121K | Buy |
111,456
+481
| +0.4% | +$527 | ﹤0.01% | 3386 |
|
|
2023
Q3 | $131K | Buy |
110,975
+6,888
| +7% | +$9.37K | ﹤0.01% | 3366 |
|
|
2023
Q2 | $147K | Buy |
+104,087
| New | +$144K | ﹤0.01% | 3386 |
|
|
2022
Q2 | – | Sell |
-101,742
| Closed | -$157K | – | 3176 |
|
|
2022
Q1 | $157K | Sell |
101,742
-18,692
| -16% | -$29K | ﹤0.01% | 2808 |
|
|
2021
Q4 | $295K | Buy |
120,434
+1,711
| +1% | +$4K | ﹤0.01% | 2710 |
|
|
2021
Q3 | $299K | Buy |
118,723
+6,208
| +6% | +$15.9K | ﹤0.01% | 2767 |
|
|
2021
Q2 | $321K | Buy |
+112,515
| New | +$291K | ﹤0.01% | 2761 |
|
|
2020
Q2 | – | Sell |
-180,344
| Closed | -$149K | – | 3088 |
|
|
2020
Q1 | $149K | Hold |
180,344
| – | – | ﹤0.01% | 2680 |
|
|
2019
Q4 | $161K | Buy |
180,344
+143
| +0.1% | +$119 | ﹤0.01% | 2800 |
|
|
2019
Q3 | $177K | Buy |
180,201
+15,993
| +10% | +$16.6K | ﹤0.01% | 2773 |
|
|
2019
Q2 | $181K | Buy |
164,208
+21,412
| +15% | +$24.7K | ﹤0.01% | 2814 |
|
|
2019
Q1 | $187K | Buy |
142,796
+14,579
| +11% | +$18.1K | ﹤0.01% | 2761 |
|
|
2018
Q4 | $117K | Buy |
128,217
+26,200
| +26% | +$40.1K | ﹤0.01% | 2862 |
|
|
2018
Q3 | $210K | Sell |
102,017
-1,772
| -2% | -$3.72K | ﹤0.01% | 2706 |
|
|
2018
Q2 | $187K | Buy |
103,789
+14,891
| +17% | +$30K | ﹤0.01% | 2752 |
|
|
2018
Q1 | $209K | Buy |
88,898
+2,257
| +3% | +$5.29K | ﹤0.01% | 2587 |
|
|
2017
Q4 | $163K | Hold |
86,641
| – | – | ﹤0.01% | 2686 |
|
|
2017
Q3 | $215K | Buy |
86,641
+686
| +0.8% | +$1.7K | ﹤0.01% | 2697 |
|
|
2017
Q2 | $237K | Buy |
85,955
+16,237
| +23% | +$45.4K | ﹤0.01% | 2676 |
|
|
2017
Q1 | $210K | Buy |
69,718
+4,833
| +7% | +$13.7K | ﹤0.01% | 2637 |
|
|
2016
Q4 | $205K | Buy |
64,885
+6,717
| +12% | +$20.6K | ﹤0.01% | 2662 |
|
|
2016
Q3 | $198K | Buy |
58,168
+3,097
| +6% | +$8.55K | ﹤0.01% | 2682 |
|
|
2016
Q2 | $126K | Buy |
55,071
+6,024
| +12% | +$14.8K | ﹤0.01% | 2875 |
|
|
2016
Q1 | $123K | Sell |
49,047
-3,810
| -7% | -$8.5K | ﹤0.01% | 2860 |
|
|
2015
Q4 | $175K | Buy |
52,857
+6,095
| +13% | +$18.2K | ﹤0.01% | 2843 |
|
|
2015
Q3 | $113K | Buy |
46,762
+2,186
| +5% | +$5.66K | ﹤0.01% | 2926 |
|
|
2015
Q2 | $131K | Sell |
44,576
-5,037
| -10% | -$19.5K | ﹤0.01% | 2975 |
|
|
2015
Q1 | $199K | Buy |
49,613
+12,143
| +32% | +$42K | ﹤0.01% | 2833 |
|
|
2014
Q4 | $113K | Buy |
37,470
+1,580
| +4% | +$4.27K | ﹤0.01% | 2943 |
|
|
2014
Q3 | $91K | Hold |
35,890
| – | – | ﹤0.01% | 2938 |
|
|
2014
Q2 | $88K | Buy |
35,890
+5,798
| +19% | +$13.1K | ﹤0.01% | 2976 |
|
|
2014
Q1 | $80K | Sell |
30,092
-2,230
| -7% | -$6.57K | ﹤0.01% | 2942 |
|
|
2013
Q4 | $94K | Hold |
32,322
| – | – | ﹤0.01% | 2961 |
|
|
2013
Q3 | $99K | Sell |
32,322
-420
| -1% | -$1.33K | ﹤0.01% | 2933 |
|
|
2013
Q2 | $105K | Buy |
+32,742
| New | +$105K | ﹤0.01% | 3232 |
|
Other funds holding LCTX
BC
DC
RA
RhumbLine Advisers's LCTX Position: Q2 2026 in Review
RhumbLine Advisers opened a new position in Lineage Cell Therapeutics (LCTX) in Q2 2026: 129,536 shares worth $170K. The stake represents ﹤0.01% of the portfolio and ranks #3347 among its holdings. This is a return to the name: RhumbLine Advisers previously reported a position in LCTX as recently as Q1 2025.
RhumbLine Advisers first reported a position in LCTX in Q2 2013 and has held it in 41 quarters since. The position peaked at $321K in Q2 2021. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.
- RhumbLine Advisers held 129,536 shares of Lineage Cell Therapeutics worth $170K as of Q2 2026.
- Lineage Cell Therapeutics was a new RhumbLine Advisers position in Q2 2026.
- Lineage Cell Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3347 holding.
- RhumbLine Advisers first reported a position in Lineage Cell Therapeutics in Q2 2013 and has held it in 41 quarters since.
- RhumbLine Advisers's Lineage Cell Therapeutics position peaked at $321K in Q2 2021.
- 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.